The European Medicines Agency adopted a negative opinion on Zevra Therapeutics' MAA, while Pomerantz LLP simultaneously investigated securities fraud claims.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency adopted a negative opinion on Zevra Therapeutics' MAA, while Pomerantz LLP simultaneously investigated securities fraud claims.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.